This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Noguchi, T. Articles by Nishiyama, M. Search for Related Content PubMed PubMed Citation Articles by Noguchi, T. Articles by Nishiyama, M.

Aberrant Methylation of DPYD Promoter, DPYD Expression, and Cellular Sensitivity to 5-Fluorouracil in Cancer Cells

Departments of ¹ Translational Cancer Research and ² Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; ³ Cancer Research Laboratory, Hanno Research Center, Taiho Pharmaceutical Co., Ltd., Saitama, Japan; and ⁴ Department of Surgery II, Faculty of Medicine, Oita University, Oita, Japan

Purpose: Dihydropyrimidine dehydrogenase (DPD), the initial rate-limiting enzyme in the degradation of 5-fluorouracil (5-FU), is known to be a principal factor in clinical responses to the anticancer agent 5-FU, and various reports have clearly demonstrated that DPD activity is closely correlated to mRNA levels. However, the regulatory mechanisms of DPD gene (DPYD) expression remain unclear. In this study, the regulatory mechanisms have been intensively studied.

Experimental Design and Results: A subcloned 3.0-kb fragment of the 5' region of DPYD contains a total of 60 CpG sites, suggesting that methylation status may affect the repression of DPYD. The clone showed various promoter activities that were largely correlated with mRNA levels in most cell lines, except HSC3 and HepG2. Bisulfite sequencing analysis revealed that various CpG sites around the transcription start site were abnormally methylated in cells with low DPYD expression: Reversal of hypermethylation by 5-azacytidine treatment significantly increased DPYD expression in HSC3 and HepG2 cells that showed strong promoter activity. In HepG2, in vitro methylation of the DPYD promoter directly decreased promoter activity, and 5-azacytidine treatment restored higher DPYD expression in a dose- and time-dependent manner, along with decreased sensitivity to 5-FU.

Conclusions: We found that DPD activity was controlled, at least in part, at the transcription level of DPYD and that aberrant methylation of the DPYD promoter region acted as one of the repressors of DPYD expression and affected sensitivity to 5-FU in cancer cells. Our new results could lead to a more precise understanding of the molecular basis of 5-FU response.

This article has been cited by other articles:

				H. H. Ezzeldin, A. M. Lee, L. K. Mattison, and R. B. Diasio Methylation of the DPYD Promoter: An Alternative Mechanism for Dihydropyrimidine Dehydrogenase Deficiency in Cancer Patients Clin. Cancer Res., December 15, 2005; 11(24): 8699 - 8705. [Abstract] [Full Text] [PDF]

				K. Ukon, K. Tanimoto, T. Shimokuni, T. Noguchi, K. Hiyama, H. Tsujimoto, M. Fukushima, T. Toge, and M. Nishiyama Activator Protein Accelerates Dihydropyrimidine Dehydrogenase Gene Transcription in Cancer Cells Cancer Res., February 1, 2005; 65(3): 1055 - 1062. [Abstract] [Full Text] [PDF]